EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
BioNTech (NASDAQ:BNTX) Given Buy Rating at Canaccord Genuity Group
Germany’s BioNTech buys China’s Biotheus in US$800 million push into cancer drugs | South China Morning Post
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up - November 14, 2024 - Zacks.com
Biontech acquiring PM-8002 through $950M Biotheus buyout | BioWorld
BioNTech to Acquire Biotheus for $800 Million to Expand Oncology Portfolio
BioNTech To Buy Biotheus In Upfront Payment Of $800 Mln
BioNTech to Acquire Biotheus to Boost Oncology Strategy | The Manila Times
Baillie Gifford & Co. Acquires 31,773 Shares of BioNTech SE (NASDAQ:BNTX)
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV) | Markets Insider
US Bancorp DE Trims Holdings in BioNTech SE (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX) Upgraded to Buy at The Goldman Sachs Group
The Goldman Sachs Group Upgrades BioNTech (NASDAQ:BNTX) to Buy
Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%
FY2024 EPS Estimates for BioNTech Cut by HC Wainwright
BioNTech SE (NASDAQ:BNTX) Shares Sold by Robeco Institutional Asset Management B.V.
Van ECK Associates Corp Sells 25,216 Shares of BioNTech SE (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX) Receives $135.54 Consensus Target Price from Brokerages
Robeco Institutional Asset Management B.V. Cuts Stake in BioNTech SE (NASDAQ:BNTX)
Van ECK Associates Corp Reduces Stock Position in BioNTech SE (NASDAQ:BNTX)
BioNTech stock target cut to $122 from $132 by TD Cowen By Investing.com
TD Cowen Has Lowered Expectations for BioNTech (NASDAQ:BNTX) Stock Price
BioNTech (NASDAQ:BNTX) Announces Quarterly Earnings Results
BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Advancements ... By GuruFocus
BMO raises BioNTech target to $126 on strong revenue By Investing.com
Earnings call: BioNTech reports growth in oncology and vaccine sectors By Investing.com
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update | The Manila Times
BioNTech Q3 Net Profit Rises; Backs FY24 Revenue Outlook Range, But At The Low End
BofA maintains Buy on BioNTech, price target at $150 By Investing.com
Adapted coronavirus vaccines drive BioNTech sales
Lodestone Wealth Management LLC Invests $8.37 Million in BioNTech SE (NASDAQ:BNTX)
BioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
abrdn plc Acquires 173,969 Shares of BioNTech SE (NASDAQ:BNTX)
Blue Trust Inc. Increases Stock Position in BioNTech SE (NASDAQ:BNTX)
BioNTech to Host Innovation Series R&D Day on November 14, 2024 | The Manila Times
International Assets Investment Management LLC Takes Position in BioNTech SE (NASDAQ:BNTX)
China Universal Asset Management Co. Ltd. Buys 7,340 Shares of BioNTech SE (NASDAQ:BNTX)
Metastatic Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
BioNTech SE (NASDAQ:BNTX) Sees Significant Increase in Short Interest
BioNTech (BNTX) Set to Announce Earnings on Monday
DekaBank Deutsche Girozentrale Has $56.89 Million Position in BioNTech SE (NASDAQ:BNTX)
Will Non-COVID Drugs Again Boost Pfizer's Top Line in Q3 Earnings? - October 28, 2024 - Zacks.com
BioNTech to Report Q3 Earnings: Is a Beat in the Cards? - October 25, 2024 - Zacks.com
Osiris Therapeutics (OTCMKTS:OSIR) versus BioNTech (NASDAQ:BNTX) Financial Review
BioNTech (NASDAQ:BNTX) PT Raised to $132.00 | MarketBeat
TD Cowen maintains Hold rating on BioNTech stock with raised price target By Investing.com
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024 | The Manila Times
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat | Morningstar
Vontobel Holding Ltd. Has $2.04 Million Position in BioNTech SE (NASDAQ:BNTX)
BioNTech (NASDAQ:BNTX) Trading Down 3.3% - What's Next?
BioNTech shares slip as FDA places partial clinical hold on lung cancer study By Investing.com
BioNTech SE : FDA has placed partial clinical hold on two-stage, open-label, randomized Phase 3 trial, PRESERVE-003 By Investing.com
GSK fires pair of COVID and RSV lawsuits at Moderna
